Securities Class Action Filed Against Microvast as Solvency and Legal Risks Mount

What happened

Rosen Law Firm announced a securities class action against Microvast Holdings on behalf of investors who purchased shares between April 1, 2025 and March 16, 2026, a period culminating in the company's 10-K filing that revealed going-concern doubts and a subsequent 46% stock drop. This lawsuit adds legal liability risk and potential settlement costs to an already strained balance sheet, where operating cash burn of $22.8 million in Q1 2026 and a $76.5 million related-party convertible loan maturing May 28, 2026 threaten near-term liquidity. The class period covers a time when Microvast's revenue fell 48% YoY in Q1 2026 and gross margin compressed due to lower utilization, yet management had previously highlighted record revenues in prior quarters, creating a stark contrast that plaintiffs may argue misled investors. While the fundamental operational thesis remains dependent on backlog conversion and Huzhou Phase 3.2 ramp, the lawsuit introduces a new overhang that could drain management attention and cash resources. For patient investors, the WAIT rating is reinforced, as legal proceedings typically take years and the immediate solvency catalysts—particularly the May convertible maturity—must be resolved before any share price recovery can materialize.

Implication

Investors should remain on the sidelines as the securities lawsuit compounds existing going-concern risks. The immediate priority is the May 28 convertible loan resolution; failure to convert or extend would likely accelerate equity issuance at depressed prices. Even if the company clears that hurdle, the class action could lead to settlement costs or distract management from operational turnaround. The thesis now requires not only shipment recovery and margin stabilization but also legal liability containment. A re-assessment is warranted after Q2 2026 results and any update on the lawsuit's progress.

Thesis delta

The class action adds a material legal risk that was not fully priced into the existing going-concern and operational risks. While the core thesis—that returns depend on solvency resolution and shipment recovery—remains intact, the lawsuit increases the probability of value-destructive outcomes such as forced equity issuance or cash settlement. Investors should demand a wider margin of safety, with the attractive entry price potentially moving lower to $1.00 or below to account for the new uncertainty.